No ME1 inhibitors are currently being evaluated in clinical trials, although a few small-molecule ME2 inhibitors were discovered in pre-clinical trials.21, 22, 23 A treatment strategy combining ME1 inhibitors with inhibition of glycolysis, NADPH-producing enzymes, or redox-regulating enzymes would provide an effective therapeutic option for some types of cancer. Here, ME2 is linked to cancer.